Manufactures high-purity, animal-free growth factors and complex proteins. Based on Cambridge Science Park, Qkine combine proprietary production processes developed at University of Cambridge with protein engineering to develop unique products that address fundamental biological and scale-up challenges for the fast-growing stem cell, organoid, regenerative medicine and cellular agriculture sectors.
EIS Fund: Case Studies
Below are a few examples of investments that the
Oxford Innovation EIS Growth Fund has made since launching.

Qkine
Investment Date:
November 2022
Since Investment:
The company has seen a 2.8x valuation increase.

Anaphite
A technology company developing graphene enhanced cathodes and novel coating methods that deliver step change improvements in charge speed, capacity and cost of batteries for electric vehicles. Founded in 2018, Anaphite is driving a global transition to sustainable energy by harnessing the amazing properties of graphene. It’s proprietary compositing process enables the incorporation of low-cost graphene into existing Li-ion battery cathode active materials to help power the sustainable energy revolution. Their fully formulated electrode powder produces better conductive networks in the coated electrode which can enable electric vehicles to fast charge in 5 minutes and at a lower cost. The company is making good technical progress.
Investment Date:
July 2022
Since Investment:
They’ve raised a £10.4m Series A round led by World Fund (Germany).

Wayland Additive
Enabling high value, mature technology transfer from the semiconductor industry to the additive manufacturing industry with its effective and accessible electron beam technology.
Wayland has built significant commercial momentum with three of its Calibur3 machines already shipped and a good sales pipeline. The company has seen significant valuation growth.
Investment Date:
November 2021
Since Investment:
They’ve proven the technology, sold commercially into several clients and have seen a valuation increase of over 5x,

Oxford Medical Products
Oxford Medical Products have developed Sirona, a disruptive solution to the obesity crisis. Obesity is a pandemic with almost one third of adults overweight or obese, representing a global market of $160 billion. Sirona is a long-acting hydrogel pill that acts like a gastric balloon. It expands & stays in the stomach for several weeks causing a sensation of satiety, suppressing the taker’s appetite, before breaking down and passing naturally.
Investment Date:
February 2022
Since Investment:
The company has successfully completed human clinical trials and is planning a Series A Investment round in 2025.

Interpac
Interpac is disrupting the cardboard manufacturing industry by building a cold corrugation machine. The cardboard industry hasn’t seen a new process for manufacturing for decades and was in need of disruption. The cold corrugation process means there’s no need for steam, which causes a drastic cut in the cost and equipment required to corrugate cardboard, without any compromise on quality. It is also more environmentally friendly.
Investment Date:
March 2022 and September 2023
Since Investment:
The company has built, tested and sold their first machine. Since initial investment there has been a 3.1x valuation increase.
If you are interested in investing in the current Oxford Innovation EIS Growth Fund, you can find out more on the Fund page.
Companies interested in receiving investment from the Oxford Innovation EIS Growth Fund should complete the Company Registration Form.